 |
Abuse, Addiction, and Pain Relief: Time for Change CME/CE Presenters' Names: Herbert D. Kleber, MD, Rollin M. Gallagher, MD, MPH, Eugene R. Viscusi, MD Author Information and Disclosures Release Date: April 22, 2008; Valid for credit through April 23, 2009 | Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians;
Pharmacists - 1.0 ACPE continuing education credits for pharmacists (0.1 CEUs) | | This activity consists of a downloadable slide presentation with audio. This program takes approximately 1 hour to complete.
To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the educational content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME/CE ActivityThis live event has already occurred. For the archived version of this event and to participate in the CME activity, please click on the link below.
This activity is jointly sponsored by   In collaboration with the National Institute on Drug Abuse  Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 SynerMed® Communications. |
|
|
Learning Objectives Upon completion of this activity, the participants should be better able to: - Specify the impact of the undertreatment of pain and inadequate pain relief
- Identify key issues surrounding the treatment of
chronic pain with scheduled and nonscheduled opioid analgesics
- Outline the risk/benefit ratios of current and future prescription analgesics and formulations
- Cite the federal regulations regarding prescription pain medications
- Review national surveillance/monitoring data
- Identify appropriate roles of the primary care physician and pain specialist in the management of patients with
pain
Disclosures Rollin M. Gallagher, MD, MPH
Dr. Gallagher has no real or apparent conflicts of interest to report.
Herbert D. Kleber, MD
Dr. Kleber has received consulting fees from Abbott Laboratories, Alkermes, and
Grünenthal.
Eugene R. Viscusi, MD
Dr. Viscusi has received consulting fees from Adolor Corporation, Anesiva, Inc., Cadence Pharmaceuticals, Johnson & Johnson Pharmaceutical, and YM BioSciences Inc. He has received fees for non-CME services from EKR Therapeutics Inc. He has also performed contracted research for Cadence Pharmaceuticals, Wyeth Pharmaceuticals, Johnson & Johnson Pharmaceutical, and YM
BioSciences Inc.
Jonathan Kamien, PhD
Dr. Kamien owns stock in Johnson & Johnson Pharmaceutical. Dr. Kamien's spouse owns stocks and options in Schering Plough Corporation.
Rick Chavez, MD
Dr. Chavez has no real or apparent conflicts of interest to report.
Theodore J. Cicero, PhD
Dr. Cicero has received consulting
fees from Abbott Laboratories and Janssen-Ortho, Inc., Canada, and has performed contracted research for Janssen-Ortho, Inc., Canada.
Howard A. Heit, MD
Dr. Heit has received consulting fees from Abbott Laboratories, Alpharma, Inc., Cephalon, Inc., Endo Pharmaceuticals, Inc., King Pharmaceuticals, Inc., and Purdue Pharma, L.P.
Bill McCarberg, MD
Dr. McCarberg has received
consulting fees for non-CME services from Alpharma, Inc., Cephalon, Inc., Endo Pharmaceuticals, Ligand Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Inc., Ortho-McNeil Pharmaceutical, Inc., and Pfizer Inc.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME
activity:
Ron Hoagland
Mr. Hoagland has no real or apparent conflicts of interest to report.
Otto Ratz, MD
Dr. Ratz has no real or apparent conflicts of interest to report.
Aliki O'Neil
Ms. O'Neil has no real or apparent conflicts of interest to report.
Jan Hixon, RN
Ms. Hixon has no real or apparent conflicts of interest to report.
Linda Graham, RN
Ms. Graham has no real or apparent conflicts of interest to report.
Trace Hutchison, PharmD
Ms. Hutchison has no real or apparent conflicts of interest to report.
|
|
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and SynerMed ® Communications. PIM is accredited by the ACCME to provide continuing medical education for physicians.
Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
 The Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Program Number - 809-999-08-041-L01-P)
Contact This Provider
|
|
